journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Vaccines

journal
https://www.readbyqxmd.com/read/28535704/pneumococcal-conjugate-vaccines-in-latin-america-are-pcv10-and-pcv13-similar-in-terms-of-protection-against-serotype-19a
#1
Maria L Avila-Aguero, Rolando Ulloa-Gutierrez, Luiza H Falleiros-Arlant, Oscar Porras
No abstract text is available yet for this article.
May 24, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28532186/bcg-and-protection-against-inflammatory-and-auto-immune-diseases
#2
Magdalena Kowalewicz-Kulbat, Camille Locht
Bacillus Calmette-Guérin (BCG) is the only available vaccine against tuberculosis. Although its protective efficacy against pulmonary tuberculosis is still under debate, it provides protection against other mycobacterial diseases. BCG is also an effective therapy against superficial bladder cancer and potentially decreases overall childhood mortality. Areas covered. The purpose of this paper is to provide a state-of-the-art summary of the beneficial effects of BCG in inflammatory and auto-immune diseases. As a strong inducer of Th1 type immunity, BCG has been reported to protect against atopic conditions, such as allergic asthma, a Th2-driven disorder...
May 22, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28532182/tackling-a-novel-lethal-virus-a-focus-on-h7n9-vaccine-development
#3
Irina Isakova-Sivak, Larisa Rudenko
Avian-origin H7N9 influenza viruses first detected in humans in China in 2013 continue to cause severe human infections with a mortality rate close to 40%. These viruses are acknowledged as the subtype most likely to cause the next influenza pandemic. Areas covered: Here we review published data on the development of H7N9 influenza vaccine candidates and their evaluation in preclinical and clinical trials identified on PubMed database with the term "H7N9 influenza vaccine". In addition, a search with the same term was done on ClinicalTrials...
May 22, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28525963/the-use-of-transgenic-parasites-in-malaria-vaccine-research
#4
Ahmad Syibli Othman, Catherin Marin-Mogollon, Ahmed M Salman, Blandine M Franke-Fayard, Chris J Janse, Shahid M Khan
Transgenic malaria parasites expressing foreign genes, for example fluorescent and luminescent proteins, are used extensively to interrogate parasite biology and host-parasite interactions associated with malaria pathology. Increasingly transgenic parasites are also exploited to advance malaria vaccine development. Areas Covered: We review how transgenic malaria parasites are used, in vitro and in vivo, to determine protective efficacy of different antigens and vaccination strategies and to determine immunological correlates of protection...
May 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28525961/passive-and-active-immunization-against-respiratory-syncytial-virus-for-the-young-and-old
#5
Tonya Villafana, Judith Falloon, M Pamela Griffin, Qing Zhu, Mark T Esser
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide and also causes significant disease in the elderly. Despite 60 years of RSV research and vaccine development, there is only one approved medicine to prevent RSV infections. Palivizumab, a monoclonal antibody (mAb) against the RSV fusion (F) protein, is indicated for preterm infants and children at high-risk for RSV infections. It is an active time in RSV vaccine and mAb development with 14 vaccines and 2 mAbs currently being tested in clinical trials as of 13 February 2017...
May 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28486850/vaccine-profile-of-herpes-zoster-hz-su-subunit-vaccine
#6
Anthony L Cunningham, Thomas Heineman
Herpes zoster (HZ) causes an often severe and painful rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN) and by dissemination in immune-compromised patients. HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age-related or other causes of decreased T cell immunity. A live attenuated vaccine boosts this immunity and provides partial protection against HZ, but this decreases with age and declines over 8 years. Areas covered: A new HZ subunit (HZ/su) vaccine combines a key surface VZV glycoprotein (E) with a T cell-boosting adjuvant system (AS01B) and is administered by two intramuscular injections two months apart...
May 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28460594/a-trivalent-inactivated-influenza-vaccine-vaxigrip%C3%A2-summary-of-almost-50-years-of-experience-and-more-than-1-8-billion-doses-distributed-in-over-120-countries
#7
Margaret Haugh, Viviane Gresset-Bourgeois, Bérengère Macabeo, Anne Woods, Sandrine I Samson
Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant body of evidence that confirms the efficacy, effectiveness, immunogenicity, and safety of Vaxigrip in healthy individuals of all ages and at-risk populations is summarized. The results from at least 15 randomized efficacy trials and 15 other studies have demonstrated that vaccination with Vaxigrip is efficacious against various clinical endpoints...
May 10, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447884/do-micrornas-play-a-role-in-the-activity-of-plant-based-vaccines
#8
Sergio Rosales-Mendoza, Jorge A Salazar-González
An important trend in vaccinology is the development of oral vaccines based on genetically modified plants. Areas covered: Several studies have suggested that dietary microRNAs from plants and other organisms are bioavailable upon oral ingestion exerting biological events in the host such as the modulation of gene expression in several cell types. Since oral plant-based vaccines rely on whole cells as vaccine delivery vehicles, miRNAs could play a role in the immunogenic activity of this type of vaccine. In the present report, this hypothesis is discussed under the light of recent evidence on the immunomodulatory activity exerted by miRNAs using in vitro and in vivo evaluations...
May 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28437234/poliovirus-vaccination-during-the-endgame-insights-from-integrated-modeling
#9
Radboud J Duintjer Tebbens, Kimberly M Thompson
Managing the polio endgame requires access to sufficient quantities of poliovirus vaccines. After oral poliovirus vaccine (OPV) cessation, outbreaks may occur that require outbreak response using monovalent OPV (mOPV) and/or inactivated poliovirus vaccine. Areas covered: We review the experience and challenges with managing vaccine supplies in the context of the polio endgame. Building on models that explored polio endgame risks and the potential mOPV needs to stop outbreaks from live poliovirus reintroductions, we conceptually explore the potential demands for finished and bulk mOPV doses from a stockpile in the context of limited shelf-life of finished vaccine and time delays to convert bulk to finished vaccine...
May 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28434256/a-bioinformatics-roadmap-for-the-human-vaccines-project
#10
Richard H Scheuermann, Robert S Sinkovits, Theodore Schenkelberg, Wayne C Koff
Biomedical research has become a data intensive science in which high throughput experimentation is producing comprehensive data about biological systems at an ever-increasing pace. The Human Vaccines Project is a new public-private partnership, with the goal of accelerating development of improved vaccines and immunotherapies for global infectious diseases and cancers by decoding the human immune system. To achieve its mission, the Project is developing a Bioinformatics Hub as an open-source, multidisciplinary effort with the overarching goal of providing an enabling infrastructure to support the data processing, analysis and knowledge extraction procedures required to translate high throughput, high complexity human immunology research data into biomedical knowledge, to determine the core principles driving specific and durable protective immune responses...
May 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447498/regulating-vaccines-at-the-fda-development-and-licensure-of-zika-vaccines
#11
Marion F Gruber, Philip R Krause
No abstract text is available yet for this article.
May 4, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28431490/new-challenges-in-therapeutic-vaccines-against-hiv-infection
#12
Lorna Leal, Constanza Lucero, Josep M Gatell, Teresa Gallart, Montserrat Plana, Felipe García
There is a growing interest in developing curative strategies for HIV infection. Therapeutic vaccines are one of the most promising approaches. We will review the current knowledge and the new challenges in this research field. Areas covered: PubMed and ClinicalTrial.gov databases were searched to review the progress and prospects for clinical development of immunotherapies aimed to cure HIV infection. Dendritic cells (DC)-based vaccines have yielded the best results in the field. However, major immune-virologic barriers may hamper current vaccine strategies...
May 4, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28425834/rift-valley-fever-vaccines-an-overview-of-the-safety-and-efficacy-of-the-live-attenuated-mp-12-vaccine-candidate
#13
Tetsuro Ikegami
Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination...
May 2, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28409537/impact-of-pneumococcal-conjugate-vaccines-for-children-in-high-and-non-high-income-countries
#14
Robert Cohen, Jérémie François Cohen, Martin Chalumeau, Corinne Levy
The high level of effectiveness of pneumococcal conjugate vaccines (PCVs) was demonstrated initially in high-income countries (HICs). However, because the burden of pneumococcal diseases (PDs) is greater in non-high-income countries (NHICs) than HICs, the assessment of these vaccines in this latter setting is crucial. Areas covered: PubMed was used to search for literature related to the effectiveness of PCVs. Several studies described the effectiveness of PCVs in NHICs, and we compare the impact of PCVs on the incidence of invasive pneumococcal disease (IPD) and pneumonia in HICs and NHICs...
April 28, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28322076/closer-than-ever-to-an-ebola-virus-vaccine
#15
Logan Banadyga, Andrea Marzi
No abstract text is available yet for this article.
April 3, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447476/mtbvac-from-discovery-to-clinical-trials-in-tuberculosis-endemic-countries
#16
Dessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, Carlos Martin
BCG remains the only vaccine against tuberculosis (TB) in use today and despite its impressive global coverage, the nature of BCG protection against the pulmonary forms of TB remains subject to ongoing debate. Because of the limitations of BCG, novel TB vaccine candidates have been developed and several have reached the clinical pipeline. One of these candidates is MTBVAC, the first and only TB vaccine in the clinical pipeline to date based on live-attenuated Mycobacterium tuberculosis that has successfully entered clinical evaluation, a historic milestone in human vaccinology...
June 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28434376/pre-clinical-and-clinical-development-of-the-first-placental-malaria-vaccine
#17
Caroline Pehrson, Ali Salanti, Thor G Theander, Morten A Nielsen
Malaria during pregnancy is a massive health problem in endemic areas. Placental malaria infections caused by Plasmodium falciparum are responsible for up to one million babies being born with a low birth weight every year. Significant efforts have been invested into preventing the condition. Areas covered: Pub Med was searched using the broad terms 'malaria parasite placenta' to identify studies of interactions between parasite and host, 'prevention of placental malaria' to identify current strategies to prevent placental malaria, and 'placental malaria vaccine' to identify pre-clinical vaccine development...
June 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28425818/immunization-with-10-valent-pneumococcal-non-typeable-haemophilus-influenzae-protein-d-conjugate-vaccine-phid-cv-according-to-different-schedules-in-infants-in-south-africa-a-phase-iii-trial
#18
Shabir A Madhi, Anthonet Koen, Lisa Jose, Marta Moreira, Nadia van Niekerk, Clare Cutland, Nancy François, Javier Ruiz-Guiñazú, Juan Pablo Yarzabal, Dorota Borys, Lode Schuerman
BACKGROUND: Limited clinical data exists to assess differences between various infant pneumococcal conjugate vaccine schedules. In this trial, we evaluated immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered using 3 different immunization schedules in HIV unexposed-uninfected infants in South Africa. METHODS: In this phase III, open, single-center, controlled study (clinicaltrials.gov: NCT00829010), 300 infants were randomized (1:1:1) to 1 of 3 PHiD-CV schedules: 3-dose priming and booster (3 + 1); 3-dose priming without booster (3 + 0); or 2-dose priming and booster (2 + 1)...
June 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28375029/emerging-experience-with-meningococcal-serogroup-b-protein-vaccines
#19
REVIEW
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
May 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28359176/old-world-cutaneous-leishmaniasis-challenges-in-morocco-algeria-tunisia-and-iran-mati-a-collaborative-attempt-to-combat-the-disease
#20
Fariborz Bahrami, Gerald F Späth, Sima Rafati
Cutaneous leishmaniasis (CL) is a main public health problem in Morocco, Algeria, Tunisia and Iran, known as the MATI region. During the biennial meeting of Pasteur Institutes of the MATI region in November 2016 in Tehran, a Leishmania panel formed of scientists with different expertise in CL research from the MATI and Institut Pasteur in Paris, proposed a new consortium to develop an integrative research approach to better understand this disease. The proposed consortium synergizes three complementary thematics on Leishmania genetics, host immune response, and vector transmission...
May 2017: Expert Review of Vaccines
journal
journal
40291
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"